Value of 111In-DOTA-lanreotide and 111In-DOTA- DPhe1-Tyr3-octreotide in differentiated thyroid cancer: Results of in vitro binding studies and in vivo comparison with 18F-FDG PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 10, 2005, Pages 1144-1151

  Rodrigues, Margarida ^a,b   Traub Weidinger, Tatjana ^b,c   Leimer, Maria ^c   Li, Shuren ^c   Andreae, Fritz ^b   Angelberger, Peter ^d   Dudczak, Robert ^c   Virgolini, Irene ^a,b  

^a GENERAL HOSPITAL LINZ   (Austria)

^b Nose and Throat Medicine   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d ARC SEIBERSDORF RESEARCH GMBH   (Austria)

Author keywords

111In DOTA DPhe1 Tyr3 octreotide; 111In DOTA lanreotide; 131I whole body scintigraphy; 18F FDG PET; Thyroid cancer

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANYLTYROSINE OCTREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE IN 111; FLUORODEOXYGLUCOSE F 18; RADIOACTIVE IODINE; RADIOLIGAND; SOMATOSTATIN RECEPTOR; THYROGLOBULIN; UNCLASSIFIED DRUG; 111IN DOTA TOC; 111IN-DOTA-TOC; CYCLOPEPTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; HETEROCYCLIC COMPOUND; INDIUM 111 DOTA LANREOTIDE; INDIUM 111-DOTA-LANREOTIDE; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL; CANCER PATIENT; CELL ISOLATION; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DRUG BINDING; DRUG UPTAKE; EVALUATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING; IN VITRO STUDY; IN VIVO STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; SCINTIGRAPHY; THYROID CANCER; THYROID GLAND; TISSUE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; PROTEIN BINDING; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; FEMALE; FLUORODEOXYGLUCOSE F18; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 25144507525     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1820-1     Document Type: Article

References (39)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-48.
2. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
3. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levi EG, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996;156:2165-72.
4. Ronga G, Fiorentino A, Paserio E, Signore A, Todino V, Tummarello MA, et al. Can iodine-131 whole body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med 1990;31:1766-71.
5. 131I- accumulating pulmonary and bone metastases of differentiated thyroid cancer with low serum thyroglobulin levels - an exception in tumor follow-up? Nuklearmediziner 1987;26:139-42.
6. 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid 1997;7:669-72.
7. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 1995;60:376-80.
8. 18F] fluorode-oxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804-11.
9. 18F-FDG-PET in the follow-up of thyroid cancer. Acta Med Austriaca 2003;30:17-21.
10. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
11. 131I in the detection of differentiated thyroid cancer metastases. Nucl Med Commun 2000;21:917-23.
12. Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1998;39:870-5.
13. Chen YK, Liu FY, Yen RF, Kao CH. Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma. Acad Radiol 2003;10:835-9.
14. Virgolini I, Yang Q, Li S, Angelberger P, Neuhold N, Niederle B, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 1994;54:690-700.
15. 90Y-DOTATOC. Eur J Nucl Med 1999;26:877-86.
16. Kölby L, Wängberg B, Ahlman H, Tisell LE, Fjälling M, Forssell-Aronsson E, et al. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J Surg 1998;22:679-83.
17. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
18. 111In-DTPA-Phe-1-octreotide. Eur J Nucl Med 1996;23:1388-99.
19. 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-55.
20. 3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 2001;12 Suppl. 2:41-5.
21. Ain KB, Taylor KD, Tofiq S, Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 1997;82:1857-62.
22. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 1996;81:2541-4.
23. Sarlis NJ, Gourgiotis L, Guthrie LC, Galen B, Skarulis MC, Shawker TH, et al. In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging. Clin Nucl Med 2003;28:208-17.
24. Gorges R, Kahaly G, Muller-Brand J, Macke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001;11:647-59.
25. 1]-octreotide. A case history. Ann N Y Acad Sci 1994;733:496-506.
26. Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skamemark G. Low-energy electron emitters for targeted therapy of small tumors. Acta Oncol 2001;41:602-8.
27. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24:792-5.
28. Smith-Jones P, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999;140:5136-48.
29. Reubi JC, Schaer JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82.
30. Wu YT, Hsieh HP, Wu CY, Yu HM, Chen ST, Wang KT. Facile solid phase synthesis of octreotide analogs using p-carboxybenzaldehyde as a novel linker for anchor Fmoc-threoninol to the solid phase resin. Tetrahedron Lett 1998;39:1783-4.
31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
32. Scatchard G. The attraction of proteins for small molecules and ions. Ann N Y Acad Sci 1949;51:660-72.
33. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. The Society of Nuclear Medicine, New York; 1998.
34. Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998;39:1928-36.
35. Garin E, Devillers A, Le Cloirec J, Bernard AM, Lescouarc'h J, Herry JY, et al. Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med 1998;25:687-94.
36. Khan N, Oriuchi N, Higuchi T, Zhang H, Endo K. PET in the follow-up of differentiated thyroid cancer. Br J Radiol 2003;76:690-5.
37. Feine U, Leitzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
38. 18F]-2-fluoro-2-deoxy-D-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? Eur J Endocrinol 2003;149:293-300.
39. 3-octreotide. Eur J Nucl Med Mol Imaging 2001;28:426-34.